News

ACCURIDS launches AI-enabled EMA PMS Compliance Solution to automate data alignment and ensure readiness for XEVMPD decommissioning and EMA Strategy 2028 ahead of the Medicines for Europe conference on February 26-27, 2026.

Vietnam's government has approved a comprehensive national strategy to transform its pharmaceutical sector into a $20 billion industry by 2045, emphasizing manufacturing, regulatory upgrades, and foreign partnerships.[3]

Antengene Corporation and Shanghai Junshi Biosciences have entered a clinical collaboration to evaluate ATG-037 combined with JS207 for solid tumor treatment in Mainland China.

The European Medicines Agency updated its records on February 25, 2026, regarding the Executive Steering Group meeting focused on addressing shortages and safety issues in medicinal products supply across Europe.

China's NMPA has expanded fast-track access for overseas drugs, streamlining regulatory approvals to accelerate market entry and foster global pharmaceutical collaborations.

Diamyd Medical has finalized the clinical database for the pre-specified interim efficacy analysis in its Phase 3 DIAGNODE-3 trial evaluating the Diamyd diabetes vaccine in recently diagnosed children and adolescents with Type 1 diabetes.

Hansoh Pharmaceutical Group achieves landmark EU regulatory approval for its third-generation EGFR-TKI drug Aumolertinib Mesylate Tablets, marking a key expansion in Europe's oncology market.

AstraZeneca has partnered with the Philippine Economic Zone Authority to establish the country's first pharmaceutical innovation hub, focusing on cancer care, digital health, and research collaboration, solidifying the Philippines' position as Southeast Asia's largest pharma market.

Sumitomo Pharma detailed its R&D strategy on February 17, 2026, highlighting enzomenib confirmatory trials, nuvisertib Phase 1/2 advancements, and raguneprocel submission for Parkinson's under Sakigake designation.[2]

SGS has gained approval from Belgium's Federal Agency for Nuclear Control to resume human 14C ADME studies at its new Antwerp clinical pharmacology unit, enhancing early-phase CRO services for pharma sponsors.